Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Geert D'Haens1, Marla Dubinsky1, Taku Kobayashi1
1From the Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam (G.D.); Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York (M.D., B.E.S.); the Center for Advanced IBD Research and Treatment, Kitasato University, Kitasato Institute Hospital, Tokyo (T.K.); Guy's Hospital, St. Thomas' Hospital, and the School of Immunology and Microbial Sciences, King's College London - all in London (P.M.I.); Research Institute for IBD-HaFCED, Hamburg, Germany (S.H.); Riga Stradins University, Riga, Latvia (J.P.); Eli Lilly, Indianapolis (K.K., J.L., X.L., T.L., J.M., N.M., V.A., C.M.); and the University of California San Diego, La Jolla (W.S.).
Mirikizumab, an interleukin-23 inhibitor, effectively treats ulcerative colitis by inducing and maintaining remission. While generally safe, some patients experienced infections or cancer, requiring careful monitoring.
Area of Science:
- Gastroenterology and immunology
- Pharmacology and therapeutic interventions
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Interleukin-23 (IL-23) is a key cytokine implicated in UC pathogenesis.
- Mirikizumab is a novel p19-directed antibody targeting IL-23.
Purpose of the Study:
- To evaluate the efficacy and safety of mirikizumab in adults with moderately to severely active ulcerative colitis.
- To assess mirikizumab's ability to induce and maintain clinical remission.
- To investigate secondary endpoints including clinical response and endoscopic remission.
Main Methods:
- Two randomized, double-blind, placebo-controlled phase 3 trials (LUCENT-1 and LUCENT-2).
- Induction phase: Mirikizumab (300 mg IV q4w) vs. placebo for 12 weeks.
- Maintenance phase: Responders received Mirikizumab (200 mg SC q4w) vs. placebo for 40 weeks.
- Primary endpoint: Clinical remission at week 12 (induction) and week 40 (maintenance).
Main Results:
- Significantly higher clinical remission rates with mirikizumab vs. placebo at week 12 (24.2% vs. 13.3%) and week 40 (49.9% vs. 25.1%).
- All major secondary endpoints, including clinical response and endoscopic remission, were met.
- Nasopharyngitis and arthralgia were more frequent adverse events; opportunistic infections and cancers occurred in a small subset of patients.
Conclusions:
- Mirikizumab demonstrated superior efficacy compared to placebo for inducing and maintaining remission in moderate-to-severe ulcerative colitis.
- The safety profile showed a low incidence of serious adverse events like opportunistic infections and cancers.
- Mirikizumab represents a promising therapeutic option for ulcerative colitis management.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...